NASDAQ:VIE Viela Bio (VIE) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$53.01▼$53.0150-Day Range$52.92▼$53.2052-Week Range$25.02▼$65.00VolumeN/AAverage Volume1.07 million shsMarket Capitalization$2.91 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Viela Bio alerts: Email Address Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Viela Bio Stock (NASDAQ:VIE)Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.Read More Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. VIE Stock News HeadlinesApril 16, 2024 | finance.yahoo.comFcRn Inhibitor Market is Predicted to Grow Rapidly During the Study Period (2020–2034) | DelveInsightJanuary 29, 2024 | benzinga.comArriVent Wows Investors With Promising China-Developed Lung Cancer TreatmentJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.January 27, 2024 | bizjournals.comArriVent Biopharma issues upsized $175M IPO, becomes region's first life sciences firm to go public in 2024January 9, 2024 | seekingalpha.comArriVent Biopharma Seeks $100 Million IPO For Lung Cancer DrugJanuary 5, 2024 | marketwatch.comArriVent BioPharma Files For IPODecember 6, 2023 | finance.yahoo.comMyasthenia Gravis Treatment Market Size, Share & Growth Analysis, [2028] | With CAGR of 7.5%November 17, 2023 | benzinga.comGlobal CD19 Antibody Market and Clinical Pipeline Outlook and Competitive Landscape: Insight on 30 Key PlayersJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.November 9, 2023 | uk.finance.yahoo.comGlobal CD19 Antibody Market Projected to Exceed $10 Billion by 2028, Driven by Promising Pipeline of TherapiesNovember 3, 2023 | finance.yahoo.comGlobal CD19 Antibody Market Set to Surpass $10 Billion by 2028: A Revolutionary Era in ImmunotherapyOctober 25, 2023 | bizjournals.comAmgen’s layoffs won’t affect Horizon Therapeutics’ Rockville footprint — for nowOctober 23, 2023 | finanznachrichten.deEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical OfficerSeptember 20, 2023 | usatoday.comInside 'Elon Musk': Wild details from revealing Walter Isaacson biographyJuly 26, 2023 | nypost.comI’m an AI influencer: Followers crave my sexy snaps — but I don’t existMay 8, 2023 | marketwatch.com2023 Cutaneous Lupus Erythematosus (CLE) Treatment Market: Latest Technology Innovations and Comprehensive Growth Insights by 2031May 5, 2023 | marketwatch.comCutaneous Lupus Erythematosus (CLE) Treatment Market: Opportunities for Industry Expansion in 2030May 5, 2023 | marketwatch.com8-K: Horizon Therapeutics Public Ltd CoSee More Headlines Receive VIE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Viela Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2021Today7/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:VIE CUSIPN/A CIKN/A Webwww.vielabio.com Phone240 558 0038FaxN/AEmployees166Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($7.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-86,430,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-33.97% Return on Assets-31.49% Debt Debt-to-Equity RatioN/A Current Ratio19.51 Quick Ratio19.49 Sales & Book Value Annual Sales$50 million Price / Sales58.26 Cash FlowN/A Price / Cash FlowN/A Book Value$7.14 per share Price / Book7.42Miscellaneous Outstanding Shares54,950,000Free FloatN/AMarket Cap$2.91 billion OptionableNot Optionable Beta0.43 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Zhengbin Yao (Age 55)Chairman, Pres & CEO Comp: $846.75kMr. Mitchell Chan (Age 40)Chief Financial Officer Comp: $420.34kDr. Jörn Drappa M.D. (Age 56)Ph.D., Chief Medical Officer and Head of R&D Comp: $637.39kMr. James Paul Kastenmayer J.D. (Age 49)Ph.D., Gen. Counsel & Company Sec. Ms. Kate SurdezSr. VP & Head of HRMs. Rachel EttingerSr. Director & Head of ResearchMr. Bill ReesSr. Director & Head of Translational ScienceMr. Ted PhillipsVP & Head of Clinical OperationsMr. Dewei SheSr. Director and Head of Biostatistics, Data Management, & ProgrammingMr. Lee LevinSr. Director & Head of QualityMore ExecutivesKey CompetitorsMyovant SciencesNYSE:MYOVKura OncologyNASDAQ:KURAIronwood PharmaceuticalsNASDAQ:IRWDZymeworksNYSE:ZYMEIGM BiosciencesNASDAQ:IGMSView All Competitors VIE Stock Analysis - Frequently Asked Questions How were Viela Bio's earnings last quarter? Viela Bio, Inc. (NASDAQ:VIE) issued its quarterly earnings data on Sunday, February, 28th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.70) by $0.10. The firm had revenue of $9.34 million for the quarter, compared to analyst estimates of $5.10 million. When did Viela Bio IPO? Viela Bio (VIE) raised $150 million in an initial public offering on Thursday, October 3rd 2019. The company issued 7,500,000 shares at a price of $19.00-$21.00 per share. Goldman Sachs, Morgan Stanley and Cowen served as the underwriters for the IPO and Guggenheim Securities was co-manager. This page (NASDAQ:VIE) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viela Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viela Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.